Details for New Drug Application (NDA): 020925
✉ Email this page to a colleague
NDA 020925 describes TAVIST-1, which is a drug marketed by Haleon Us Holdings and Novartis and is included in two NDAs. Additional details are available on the TAVIST-1 profile page.
The generic ingredient in TAVIST-1 is clemastine fumarate. There are two drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the clemastine fumarate profile page.
The generic ingredient in TAVIST-1 is clemastine fumarate. There are two drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the clemastine fumarate profile page.
Summary for 020925
| Tradename: | TAVIST-1 |
| Applicant: | Haleon Us Holdings |
| Ingredient: | clemastine fumarate |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 020925
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 1.34MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Aug 21, 1992 | TE: | RLD: | Yes | |||||
Complete Access Available with Subscription
